# Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

> **NCT02071056** · — · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Leptomeningeal Metastasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02071056
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-11-25
- **Final completion:** 2015-11-25
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071056, "Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02071056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*